Zobrazeno 1 - 10
of 67
pro vyhledávání: '"H. M James Hung"'
Autor:
H. M. James Hung, John Lawrence
Publikováno v:
Statistics in Biopharmaceutical Research. 15:318-322
Over the last several decades, major adverse clinical outcomes have been studied in the form of composite endpoints in cardiovascular and renal trials. Great utilities and challenges in the use of ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9376b06ad298a07c068252ceafbc9df
https://doi.org/10.1080/19466315.2021.1945487
https://doi.org/10.1080/19466315.2021.1945487
Publikováno v:
Therapeutic Innovation & Regulatory Science. 55:197-211
Uncertain ascertainment of events in clinical trials has been noted for decades. To correct possible bias, Clinical Endpoint Committees (CECs) have been employed as a critical element of trials to ensure consistent and high-quality endpoint evaluatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508161e3f0e99e8cd5345988df1e4702
https://doi.org/10.1007/s43441-020-00206-3
https://doi.org/10.1007/s43441-020-00206-3
Autor:
H. M. James Hung, Sue-Jane Wang
Publikováno v:
Statistics in Biopharmaceutical Research. 15:249-250
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38f00b63fc34def796379a4f91f7a990
https://doi.org/10.1080/19466315.2022.2029556
https://doi.org/10.1080/19466315.2022.2029556
Publikováno v:
Statistics in Biopharmaceutical Research. 11:239-251
Polycystic kidney disease is a genetic disorder that causes cysts to grow in the kidney. It is slowly progressing and often leads to end-stage kidney disease, requiring dialysis or a transp...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00dc773160e31f096adcb736e86564c5
https://doi.org/10.1080/19466315.2019.1584913
https://doi.org/10.1080/19466315.2019.1584913
Autor:
Norman Stockbridge, Bruce Binkowitz, Mouna Akacha, H. M. James Hung, Guenther Mueller-Velten, Brian Claggett
Publikováno v:
Therapeutic Innovation & Regulatory Science. 53:387-397
Serious and chronic health conditions such as cardiovascular diseases (CVDs) are posing challenges to the health system. Recently clinical trials in these fields have focused on composite endpoints that take into account both disease-related mortalit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bc3d7fa4dd213fd4b89378f67e7bda9
https://doi.org/10.1177/2168479018784912
https://doi.org/10.1177/2168479018784912
Publikováno v:
Journal of Biopharmaceutical Statistics. 29:1116-1129
The sequential parallel comparison designhas recently been considered to solve the problem with high placebo response and the required sample size in the psychiatric clinical trials. One feature with this design is that a difference between the place
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6c901caa16367c0edd48aa42730c6f3
https://doi.org/10.1080/10543406.2019.1609014
https://doi.org/10.1080/10543406.2019.1609014
Publikováno v:
Contemp Clin Trials
We investigate selection of critical boundary functions for testing the hypotheses of two time-to-event outcomes as both primary endpoints or a primary and a secondary endpoint in group-sequential clinical trials, where (1) the effect sizes of endpoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77fceefc98db6be1689caccdf32eaf95
https://europepmc.org/articles/PMC7954908/
https://europepmc.org/articles/PMC7954908/
Publikováno v:
Journal of Biopharmaceutical Statistics. 29:1134-1136
In this rejoinder the authors stipulate further for two challenging issues. First, if placebo non-responders are selected simply by their response meeting a threshold, this selection may have miscl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce6cf4fb173fe114305c131c537d0f48
https://doi.org/10.1080/10543406.2019.1609017
https://doi.org/10.1080/10543406.2019.1609017
Autor:
Eugenio Andraca-Carrera, Thomas Gwise, Stella Grosser, Somesh Chattopadhyay, Sue Jane Wang, Anup K. Amatya, Mark Rothmann, Fraser Smith, Sylva H. Collins, Rebecca Rothwell, Yu-Ting Weng, Yute Wu, H. M. James Hung
Publikováno v:
Statistics in Biopharmaceutical Research. 13:57-58
Null hypothesis testing is a foundational stone of statistical analysis. The “p-value” has evolved to play a critical role in hypothesis testing. Nonetheless, use of p-values carries with it some c...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73b3bb13ef769881603995960eabc512
https://doi.org/10.1080/19466315.2021.1886164
https://doi.org/10.1080/19466315.2021.1886164
Publikováno v:
Statistics in Biopharmaceutical Research. 13:30-31
We are grateful for the opportunity to enjoy reading the article by Dr. Eric Gibson (Gibson 2020). The article covers a lot of important subjects concerning strength of evidence very well. The sugg...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32838b61dfa198730e9bbaa283380219
https://doi.org/10.1080/19466315.2020.1811150
https://doi.org/10.1080/19466315.2020.1811150